CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 154 enrolled
Drug / intervention
Intravitreal Aflibercept Injection (IAI)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01722045
NCT01722045Phase 4Completed
CompareCT.gov

An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration

Regeneron Pharmaceuticals·interventional·Posted Nov 6, 2012·Updated Dec 22, 2017

In Brief

A Phase 4 clinical trial evaluating Intravitreal Aflibercept Injection (IAI) for Age - Related Macular Degeneration (AMD). Completed, enrolled 154 participants across 49 sites.

Detailed Summary

This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge - Related Macular Degeneration (AMD)
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 6, 2012
Enrollment StartNov 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.7 years ago

Interventions

Intravitreal Aflibercept Injection (IAI)drug